A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Key Inclusion Criteria:

• Documented historical diagnosis of multiple myeloma (MM)

• Received 1 to 3 prior lines of antimyeloma therapy, including an immunomodulatorydrug (IMiD) and an anti-cluster of differentiation 38 (CD38) monoclonal antibody (mAb). A minimum of 2 consecutive cycles of an IMiD and an anti-CD38 mAb in anyprior line of therapy is required. The IMiD and anti-CD38 mAb do not need to be fromthe same regimen in the prior line(s) of therapy.

• Documented evidence of progressive disease by IMWG criteria based on theinvestigator's determination on or within 12 months of the last dose of the lastregimen

• Measurable disease at screening per IMWG, defined as any of the following:

• Serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or

• Light chain MM without measurable disease in the serum or urine: serum freelight chain ≥ 10 mg/dL and abnormal serum free light chain ratio

• Only individuals who are candidates to receive at least 1 of the 4 SOCT regimens (PVd, DPd, KDd, or Kd), as determined by the investigator, should be considered forthis study

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Females of childbearing potential must have a negative serum or urine pregnancy testwith a sensitivity of at least 25 mIU/mL (females who have undergone surgicalsterilization or who have been postmenopausal for at least 2 years are notconsidered to be of childbearing potential)

Key Exclusion Criteria:

• Prior B-cell maturation antigen (BCMA)-targeted therapy

• Prior T-cell engager therapy

• Prior CAR therapy or other genetically modified T-cell therapy

• Active or prior history of central nervous system (CNS) or meningeal involvement ofMM

• Cardiac atrial or cardiac ventricular MM involvement

• History of or active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMSsyndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skinchanges), or amyloidosis

• Active malignancy (other than MM) requiring ongoing treatment for disease controlwithin the last 24 months. Myelodysplastic syndrome (even without ongoing treatment)is not permitted.

• Prior auto-SCT within 12 weeks before randomization

• Prior allogeneic stem cell transplant (allo-SCT)

• High-dose (eg, cumulative > 70 mg prednisone or equivalent) systemic steroid therapyor any other form of immunosuppressive therapy within 14 days before randomization

• Live vaccine ≤ 4 weeks before randomization

• Contraindication to fludarabine or cyclophosphamide

• History of allergy or hypersensitivity to any study agent or study drug components.Individuals with a history of severe hypersensitivity reaction to dimethyl sulfoxide (DMSO) are excluded.

• Life expectancy < 12 weeks

Note: Other protocol defined Inclusion/Exclusion criteria may apply.